• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎(COVID-19)与伊朗的皮肤病学

COVID-19 and Dermatology in Iran.

机构信息

Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Clin Dermatol. 2021 Jul-Aug;39(4):703-706. doi: 10.1016/j.clindermatol.2021.05.022. Epub 2021 May 18.

DOI:10.1016/j.clindermatol.2021.05.022
PMID:34809776
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8129800/
Abstract

COVID-19 infection may affect the individuals with many underlying conditions including skin diseases. This cross-sectional study was conducted to provide an overview regarding the prevalence of COVID-19 disease in the patients with several skin diseases. Overall, 703 patients with several skin diseases participated in the study and completed our online-designed questionnaire. Among the total participants, only 32(4.6%) subjects reported the COVID-19 infection. The prevalence rate was equal to 0.04%. In the patients with psoriasis, 14 out of 322 people (4.3%) developed the COVID-19. Three out of 159 patients (1.9%) with alopecia areata had been affected with the COVID-19 and 4 (5.2%) patients with vitiligo had caught the disease. Only one subject (2%) with the lichen planus, and 6 (6.8%) patients with other skin diseases had developed the COVID-19 but in the patients with GVHD (Graft Versus Host Disease), 4 (80%) out of 5 patients had caught the COVID-19 disease. The frequency of COVID-19 infection was low in the studied population however; more studies with larger sample size are needed to determine the exact prevalence of the infection in the patients with skin diseases undergoing the treatment with several systemic medications.

摘要

COVID-19 感染可能会影响许多患有基础疾病的个体,包括皮肤病。本横断面研究旨在概述几种皮肤病患者中 COVID-19 疾病的患病率。共有 703 名患有几种皮肤病的患者参加了这项研究,并完成了我们在线设计的问卷。在所有参与者中,只有 32 名(4.6%)患者报告了 COVID-19 感染。患病率等于 0.04%。在银屑病患者中,322 人中的 14 人(4.3%)感染了 COVID-19。159 名斑秃患者中有 3 人(1.9%)感染了 COVID-19,4 名(5.2%)白癜风患者感染了 COVID-19。只有 1 名(2%)扁平苔藓患者和 6 名(6.8%)患有其他皮肤病的患者感染了 COVID-19,但在 GVHD(移植物抗宿主病)患者中,5 名患者中有 4 名(80%)感染了 COVID-19 疾病。在研究人群中,COVID-19 感染的频率较低;但需要进行更多具有更大样本量的研究,以确定正在接受多种全身性药物治疗的皮肤病患者中感染的确切患病率。

相似文献

1
COVID-19 and Dermatology in Iran.新型冠状病毒肺炎(COVID-19)与伊朗的皮肤病学
Clin Dermatol. 2021 Jul-Aug;39(4):703-706. doi: 10.1016/j.clindermatol.2021.05.022. Epub 2021 May 18.
2
Immunosuppressive and immunomodulatory therapies in dermatology and coronavirus disease 2019 (COVID-19).皮肤科免疫抑制和免疫调节治疗与 2019 年冠状病毒病(COVID-19)。
Clin Dermatol. 2021 May-Jun;39(3):517-520. doi: 10.1016/j.clindermatol.2021.01.003. Epub 2021 Feb 16.
3
Evaluation between Association of Psoriasis and Vitiligo.银屑病与白癜风关联性的评估。
J Cutan Med Surg. 2015 Mar-Apr;19(2):140-3. doi: 10.2310/7750.2014.14074. Epub 2015 Mar 11.
4
SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.伊朗 18 个城市一般人群和高风险职业人群中 SARS-CoV-2 抗体血清流行率:一项基于人群的横断面研究。
Lancet Infect Dis. 2021 Apr;21(4):473-481. doi: 10.1016/S1473-3099(20)30858-6. Epub 2020 Dec 15.
5
Profile of alopecia areata in Northern India.印度北部斑秃概况。
Int J Dermatol. 1996 Jan;35(1):22-7. doi: 10.1111/j.1365-4362.1996.tb01610.x.
6
Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease.慢性移植物抗宿主病患者的白癜风和斑秃的风险因素和特征。
JAMA Dermatol. 2015 Jan;151(1):23-32. doi: 10.1001/jamadermatol.2014.1550.
7
Does autoimmune vitiligo protect against COVID-19 disease?自身免疫性白癜风能预防 COVID-19 疾病吗?
Exp Dermatol. 2021 Sep;30(9):1254-1257. doi: 10.1111/exd.14407. Epub 2021 Jun 17.
8
COVID-19 and exacerbation of dermatological diseases: A review of the available literature.COVID-19 与皮肤疾病恶化:现有文献综述。
Dermatol Ther. 2021 Nov;34(6):e15113. doi: 10.1111/dth.15113. Epub 2021 Sep 7.
9
The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy.生物制剂治疗的银屑病患者中 SARS-CoV-2 感染的流行率和 COVID-19 病程的严重程度。
J Dermatolog Treat. 2022 May;33(3):1581-1584. doi: 10.1080/09546634.2020.1861177. Epub 2020 Dec 22.
10
A Comparison of Diagnosed Skin Diseases between the Years with and without COVID-19 Pandemic.有和无新冠疫情年份诊断皮肤病的比较。
Medicina (Kaunas). 2021 Jul 29;57(8):773. doi: 10.3390/medicina57080773.

本文引用的文献

1
Patient's perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice.患者视角:146例在实际临床实践中接受生物药物和小分子药物治疗的银屑病患者在新冠疫情期间的心理负担
J Dermatolog Treat. 2022 Mar;33(2):1185-1187. doi: 10.1080/09546634.2020.1790485. Epub 2020 Jul 9.
2
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan.41例免疫介导性炎症疾病患者的新型冠状病毒肺炎临床病程:米兰人道主义中心的经验
Pharmacol Res. 2020 Oct;160:105061. doi: 10.1016/j.phrs.2020.105061. Epub 2020 Jul 3.
3
Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy.接受长期免疫调节治疗的皮肤病患者感染新型冠状病毒肺炎的风险
J Am Acad Dermatol. 2020 Oct;83(4):1215-1218. doi: 10.1016/j.jaad.2020.06.999. Epub 2020 Jul 2.
4
Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.COVID-19 大流行期间皮肤科治疗药物的感染风险:基于证据的重新调整。
Int J Dermatol. 2020 Sep;59(9):1043-1056. doi: 10.1111/ijd.15028. Epub 2020 Jul 3.
5
Prior treatment with immunosuppressants among coronavirus disease 2019 (COVID-19) inpatients at one hospital in Spain.西班牙一家医院收治的2019冠状病毒病(COVID-19)住院患者之前使用免疫抑制剂的情况。
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):e760-e762. doi: 10.1111/jdv.16798. Epub 2020 Aug 16.
6
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment.接受生物治疗的慢性斑块状银屑病患者以及接受维持性免疫抑制治疗的肾移植受者感染新型冠状病毒肺炎(COVID-19)后住院和死亡的风险。
J Am Acad Dermatol. 2020 Jul;83(1):285-287. doi: 10.1016/j.jaad.2020.04.085. Epub 2020 Apr 21.
7
Challenges of COVID-19 pandemic for dermatology.COVID-19 大流行给皮肤科带来的挑战。
Dermatol Ther. 2020 Sep;33(5):e13430. doi: 10.1111/dth.13430. Epub 2020 Apr 30.
8
COVID-19 and immunomodulator/immunosuppressant use in dermatology.新型冠状病毒肺炎与皮肤科中免疫调节剂/免疫抑制剂的应用
J Am Acad Dermatol. 2020 May;82(5):e173-e175. doi: 10.1016/j.jaad.2020.03.046. Epub 2020 Mar 26.
9
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代,银屑病生物制剂是否应中断使用?
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
10
COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.新型冠状病毒肺炎与银屑病:是时候限制免疫抑制剂的使用了吗?呼吁采取行动。
Dermatol Ther. 2020 Jul;33(4):e13298. doi: 10.1111/dth.13298. Epub 2020 Mar 22.